Summary : IMCIVREE now available for chronic weight management in adult and pediatric patients 6…
Active Pharmaceutical Ingredients (API)
Takeda’s LIVTENCITY (Maribavir) Approved by U.S. FDA as the First and Only Treatment of Post-Transplant Cytomegalovirus (CMV), that is Resistant to other Antiviral Drugs.
SYNOPSIS: Takeda announced that U.S. FDA Approved LIVTENCITY (Maribavir) as the First and Only Treatment…
Pfizer’s XELJANZ® (Tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib)…
Zydus Cadila receives USFDA Final Approval for Nelarabine Injection a Therapeutically Generic Version of Arranon injection.
KEYPOINTS: Zydus Cadila has received final approval from the US FDA to market Nelarabine injection…
The European Commission Grants Marketing Authorization for VUMERITY® (Diroximel Fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis.
SYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established…
GlaxoSmithKline`s Nucala (Mepolizumab) gets European Approval for use in Three Additional Eosinophil-driven Diseases.
KEYPOINTS: GlaxoSmithKline (NYSE:GSK) announces that the European Commission has approved Nucala (Mepolizumab), a monoclonal antibody…
Active Pharmaceutical Ingredients (API)Risankizumab
European Commission approves AbbVie’s Skyrizi (Risankizumab) to Treat Adults with Active Psoriatic Arthritis.
KEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous…
Active Pharmaceutical Ingredients (API)Insulin
Biocon Biologics and Viatris launch Interchangeable Biosimilars SEMGLEE and Insulin Glargine Injection in US.
KEYPOINTS: Biocon Biologics and Viatris Inc have launched Semglee (insulin glargine-yfgn) injection, a branded product,…
Levodopa and Entacapone
STADA and Bioglan signed an Agreement to Increase Production Capacity to Meet Rising Demand for Parkinson’s Treatment.
KEYWORDS: Bioglan, the Swedish subsidiary of the Spanish pharmaceutical company, and STADA Arzneimittel AG have…
FDA Approves Ropeginterferon Alfa-2b-njft (Besremi) Treatment for Rare Blood Disease Polycythemia Vera (PV).
SUMMARY: PharmaEssentia Corporation a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven…